Abstract
There is no currently available solution, theoretical or empirical, to satisfactorily explain differential population frequencies and individual risk levels of prostatic hypertrophy. Since this is the most prevalent of all pathologic entities in aging males, and virtually all males can expect to develop some hyperplastic foci during the final decades of life, whether or not they result in detectable hypertrophies, it may be moot that the condition is abnormal. That it occurs so universally and is readily treatable, however, does not detract from the observation that it has long been a condition that, with many other maturity-associated setbacks, can be expected to contain the life span of some men. What appears surprising is that mortality from this not-so-benign hypertrophy, despite the development of effective modalities for repair and cure, persists at remarkably high levels in some cultures.
This is a preview of subscription content, log in via an institution.
Buying options
Tax calculation will be finalised at checkout
Purchases are for personal use only
Learn about institutional subscriptionsPreview
Unable to display preview. Download preview PDF.
References
Amaku EO, Da Rocha-Afodu T, Elebute EA: Prostatic obstruction in Nigerians. W Afr Med J 20: 189–194, 1971
Armenian HK, Lilienfeld AM, Diamond EL, Bross IDJ: Relation between benign prostatic hyperplasia and cancer of the prostate. Lancet 2:115– 117, 1974
Ashley JB: Observations on the epidemiology of prostatic hyperplasia in Wales. Br J Urol 38: 567–569, 1966
Bourke JB, Griffin JP: Blood groups in benign and malignant prostatic hypertrophy. Lancet 2: 1279–1280, 1962
Bourke JB, Griffin JP: Hypertension, diabetes mellitus and blood groups in benign prostatic hypertrophy. Br J Urol 38: 18–23, 1966
Bourke JB, Griffin JP: Diabetes mellitus in patients with benign prostatic hyperplasia. Br Med J 4:492– 493, 1968
D’Aunoy R, Schenken JR, Burns EL: The relative incidence of hyperplasia of the prostate in the white and colored races of Louisiana. South Med J 32: 47–52, 1939
Derbes VDP, Leche SM, Hooker CW: The incidence of benign prostatic hypertrophy among the whites and negroes in New Orleans. J Urol 38:383– 388, 1937
Dodge OG: Carcinoma of the prostate in Uganda Africans. Cancer 16: 1264–1268, 1963
Finkle AL: The relationship of sexual habits to benign prostatic hypertrophy. Med Aspects Hum Sexualr 1: 24–25, 1967
Greenwald P, Kirmss V, Polan AK, Dick VS: Cancer of the prostate among men with benign prostatic hyperplasia. J Natl Cancer Inst 53: 335–340, 1974
Haugen OA: Discussion. In Grayhack JT, Wilson JD, Sherbenske MJ (eds.): Benign Prostatic Hyperplasia. DHEW Publ. No. (NIH)76–1113, US Gov’t Printing Office, Washington, DC, 1976, p 117
Hechter O: Reflections on the NIH workshop on BPH. In Grayhack JT, Wilson JD, Sherbenske21 Origins, Distribution, and Risk MJ (eds): Benign Prostatic Hyperplasia. DHEW Publ. No. (NIH)76-1113, US Gov’t Printing Office, Washington, DC, 1976, pp 269–281
Houston W: The Bantu prostate: a study of prostatic disease in central Africa. J Urol 99: 316–320, 1968
Ismail AAA, Harkness RA: Urinary testosterone excretion in men in normal and pathological conditions. Acta Endocrinol (Copenh) 56: 469–480, 1967
Kambal A: Prostatic obstruction in Sudan. J Urol 49: 139–141, 1977
Lissoos I: Simple prostatic hyperplasia in the Bantu. S Afr Med J 47: 389–391, 1973
Moore RA: Benign hypertrophy of the prostate: a morphological study. J Urol 50: 680–710, 1943
Moore RA: Benign hypertrophy and carcinoma of the prostate. Surgery 16: 152–167, 1944
Odunjo EO, Elebute EA: Chronic prostatitis in BPH. Br J Urol 43: 333–336, 1971
Pond DA, Maratos J: Psychosocial inter-relations of benign prostatic hypertrophy. J Psychosom Res 21: 201–206, 1976
Richardson IM: Prostatic cancer and social class. Br J Prev Soc Med 19: 140–142, 1965
Roberts HJ: The role of diabetogenic hyperinsulinism in the pathogenesis of prostatic hyperplasia and malignancy. J Am Geriatr Soc 14: 795–825, 1966
Robson MC: The incidence of benign prostatic hypertrophy and prostatic carcinoma in cirrhosis of the liver. J Urol 92: 307–310, 1964
Rotkin ID: Epidemiology of benign prostatic hypertrophy: review and speculations. In Grayhack JT, Wilson JD, Sherbenske MJ (eds.): Benign Pros¬tatic Hyperplasia. DHEW Publ. No. (NIH)76-1113, US Gov’t Printing Office, Washington, DC, 1976, pp 105–117
Siiteri PK, Wilson JD: Dihydrotestosterone in prostatic hypertrophy. J Clin Invest 49: 1737–1745, 1970
Tveter KJ: Some aspects of the pathogenesis of prostatic hyperplasia. Acta Pathol Microbiol Scand [A] (Suppl) 248: 167–174, 1974
Van der Reis L: Benign prostatic hypertrophy and coronary heart disease: correlation of coincidence? J Am Geriatr Soc 7: 866–869, 1959
Whitmore WF Jr: The natural history of prostatic cancer. Cancer 32: 1104–1112, 1973
Whitmore WF III: Benign prostatic hyperplasia; widespread and sometimes worrisome. Geriatrics 36: 119–136, 1981
Wilson JD: The pathogenesis of benign prostatic hyperplasia. Am J Med 68: 745–756, 1980
World Health Statistics Annual: Vital Statistics and Causes of Death, Vol 1. World Health Organization, Geneva, 1980.
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1983 Springer-Verlag New York Inc.
About this chapter
Cite this chapter
Rotkin, I.D. (1983). Origins, Distribution, and Risk of Benign Prostatic Hypertrophy. In: Hinman, F., Boyarsky, S. (eds) Benign Prostatic Hypertrophy. Springer, New York, NY. https://doi.org/10.1007/978-1-4612-5476-8_2
Download citation
DOI: https://doi.org/10.1007/978-1-4612-5476-8_2
Publisher Name: Springer, New York, NY
Print ISBN: 978-1-4612-5478-2
Online ISBN: 978-1-4612-5476-8
eBook Packages: Springer Book Archive